Arcutis Biotherapeutics Inc. Common Stock (NASDAQ:ARQT)

Home >> Stock >> Arcutis Biotherapeutics Inc. Common Stock >> Reports

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California....

+See More

Blog+More

Warren Buffett offloads a few stocks from the Berkshire Hathaway portfolio in November 2018.

Peter Prince

2018-11-27 10:37:00 Tuesday ET

Warren Buffett offloads a few stocks from the Berkshire Hathaway portfolio in November 2018.

Warren Buffett offloads a few stocks from the Berkshire Hathaway portfolio in mid-November 2018. The latest S.E.C. report shows that the Oracle of Omaha sol

+See More

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fundamental analysis of Intuit (U.S. stock symbol: $INTU).

Dan Rochefort

2025-10-12 13:32:00 Sunday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fundamental analysis of Intuit (U.S. stock symbol: $INTU).

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund

+See More

Capital gravitates toward key profitable mutual funds until the marginal asset return equilibrates near the core stock market benchmark.

Peter Prince

2019-07-27 17:37:00 Saturday ET

Capital gravitates toward key profitable mutual funds until the marginal asset return equilibrates near the core stock market benchmark.

Capital gravitates toward key profitable mutual funds until the marginal asset return equilibrates near the core stock market benchmark. As Stanford finance

+See More

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization.

Laura Hermes

2019-09-09 20:38:00 Monday ET

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization.

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization. As Federal Reserve Ch

+See More

The European Central Bank expects to further reduce negative interest rates with new quantitative government bond purchases.

Laura Hermes

2019-10-17 08:35:00 Thursday ET

The European Central Bank expects to further reduce negative interest rates with new quantitative government bond purchases.

The European Central Bank expects to further reduce negative interest rates with new quantitative government bond purchases. The ECB commits to further cutt

+See More

Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation.

Rose Prince

2018-06-21 10:42:00 Thursday ET

Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation.

Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation. European Union retaliator

+See More